Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-04-10 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary shareholders meeting of Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, agenda items, voting results, and legal opinions. The content focuses on shareholder meeting decisions, including changes in registered capital, company type, amendments to the articles of association, governance-related system revisions, and election of independent directors. It also includes voting statistics and legal validation of the meeting process. This type of document is a formal announcement of voting results from a shareholders meeting, not the meeting materials themselves or a full annual/interim report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains substantive voting results and resolutions, not just a notice of report publication or a brief regulatory filing. Hence, the classification is DVA with high confidence.
2024-04-10 Chinese
浙江天册律师事务所关于浙江海昇药业股份有限公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures and voting results of the 2024 first extraordinary general meeting (临时股东大会) of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is typically associated with announcements of voting results or legal opinions related to shareholder meetings. Given the detailed voting results and the legal opinion on the validity of the meeting and votes, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains substantive content about voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the classification is DVA with high confidence.
2024-04-10 Chinese
浙江海昇药业股份有限公司投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" of Zhejiang Haisheng Pharmaceutical Co., Ltd., approved by the board on March 22, 2024, and pending submission to the shareholders' meeting. It details the company's policies, principles, organizational structure, and procedures for managing investor relations, including communication methods, responsibilities, and compliance with laws and regulations. There are no financial statements, earnings data, or audit information. The document is a governance-related policy document rather than a financial report or announcement of voting results. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Voting Results. It is a governance-related internal rules document about investor relations management, which aligns best with Governance Information (CGR). The document length is 4307 characters, which is substantive and not a brief announcement or certification. Therefore, the classification is Governance Information (CGR) with high confidence.
2024-03-25 Chinese
关于使用银行承兑汇票及自有资金等方式支付募投项目所需资金并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the use of bank acceptance bills and own funds to pay for funds required for investment projects and the replacement of these funds with raised funds. It includes details about the approval by the board and supervisory committee, regulatory approvals from the China Securities Regulatory Commission and Beijing Stock Exchange, and opinions from the sponsor institution. The document is a formal disclosure about the company's capital management and fundraising usage, not a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management report. The document is a regulatory announcement about capital usage and fundraising replacement, fitting the category of Capital/Financing Update (CAP). The document length is 2774 characters, which is typical for an announcement rather than a full report. Therefore, the best classification is Capital/Financing Update (CAP).
2024-03-25 Chinese
浙江海昇药业股份有限公司累积投票实施细则
Governance Information Classification · 95% confidence The document is titled as a detailed implementation rule for cumulative voting by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes detailed procedural rules for voting, election principles for directors and supervisors, and operational procedures related to cumulative voting. The document is a formal announcement of a governance-related policy approved by the board and pending shareholder meeting approval. It does not contain financial statements, audit results, earnings data, or any report publication announcement. It is clearly related to corporate governance and board election procedures, which fits the category of Governance Information (CGR). The document length is 3114 characters, which is relatively short but contains substantive governance content rather than a mere announcement or notice. Therefore, the best classification is Governance Information (CGR).
2024-03-25 Chinese
浙江海昇药业股份有限公司利润分配管理制度
Governance Information Classification · 95% confidence The document is titled as a '利润分配管理制度' which translates to 'Profit Distribution Management System' of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the company's profit distribution policies, procedures, principles, and supervisory mechanisms. It includes sections on the approval process by the board and shareholders, dividend distribution methods, and conditions for profit distribution. The document is a formal policy or governance document rather than a financial report or announcement of voting results. It is not an annual or interim report, earnings release, or a regulatory filing announcing a report. It is a governance-related document outlining internal rules and policies regarding profit distribution. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3844 characters, which is substantial enough to be a full policy document rather than a brief announcement.
2024-03-25 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.